Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 15/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 8/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 3/20 | 1.00 |
| ▸ | EIF2AK1 | Q9BQI3 | 3/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | YES1 | P07947 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | MAP3K9 | P80192 | 2/20 | 1.00 |
| ▸ | MAP3K10 | Q02779 | 2/20 | 1.00 |
| ▸ | MERTK | Q12866 | 2/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 2/20 | 1.00 |
| ▸ | NTRK3 | Q16288 | 2/20 | 1.00 |
| ▸ | NTRK2 | Q16620 | 2/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29403654 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL29384284 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL30500616 | 1.00 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL28589747 | 0.93 | EIF2AK3 (0.87) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869189 | 0.90 | RIPK1 (0.82) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869448 | 0.90 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL870488 | 0.90 | RIPK1 (0.81) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL869419 | 0.90 | EIF2AK3 (1.00) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL28814384 | 0.90 | EIF2AK3 (0.86) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 | |
| SCHEMBL29433603 | 0.90 | EIF2AK3 (0.81) | EIF2AK3RIPK1EIF2AK2EIF2AK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| US-11026945-B2 | Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-06-08 | — | — | US | claimed |
| US-10668017-B2 | Perivascular drug delivery system | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2020-06-02 | — | — | US | claimed |
| US-20200054638-A1 | PROTEIN KINASE RNA-LIKE ENDOPLASMIC RETICULUM KINASE (PERK) INHIBITORS FOR PREVENTION AND/OR TREATMENT OF LUNG INJURY AND/OR INFLAMMATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2020-02-20 | — | — | US | claimed |
| US-20180042844-A1 | PERIVASCULAR DRUG DELIVERY SYSTEM | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | claimed |
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | claimed |
| CN-102917588-B | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2014-10-08 | — | — | CN | claimed |
| US-20140227289-A1 | COMPOUNDS AND METHODS FOR TREATING INSULIN RESISTANCE SYNDROME | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-08-14 | — | — | US | claimed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | claimed |
| EP-2549868-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | claimed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | claimed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | claimed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| US-20240197760-A1 | ACTIVATORS OF INTEGRATED STRESS RESPONSE PATHWAY FOR PROTECTION AGAINST FERROPTOSIS | Burke Neurological Institute | 2024-06-20 | — | — | US | disclosed |
| WO-2024009280-A1 | INTEGRATED STRESS RESPONSE INHIBITORS AND METHODS OF USING THE SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-01-11 | — | — | WO | disclosed |
| EP-2968347-B1 | MODULATORS OF THE EIF2ALPHA PATHWAY | UNIV CALIFORNIA (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119663-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | EIF2AK3 2073/4885RIPK1 160/4885EIF2AK2 1560/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885RIPK1 218/4885EIF2AK2 174/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885RIPK1 218/4885EIF2AK2 174/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | EIF2AK3 3716/4885RIPK1 309/4885EIF2AK2 4287/4885 |
| US-20200054638-A1 | PROTEIN KINASE RNA-LIKE ENDOPLASMIC RETICULUM KINASE (PERK) INHIBITORS FOR PREVENTION AND/OR TREATMENT OF LUNG INJURY AND/OR INFLAMMATION | DDIT3, ERN2, ERN1 | EIF2AK3 31/4885RIPK1 193/4885EIF2AK2 6/4885 |
| US-11026945-B2 | Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibitors for prevention and/or treatment of lung injury and/or inflammation | DDIT3, ERN2, ERN1 | EIF2AK3 31/4885RIPK1 193/4885EIF2AK2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.